Phase II Trial of SBRT + or - IMRT in Treatment of Patients With Clinically Confined Prostate Adenocarcinoma

Inclusion Criteria: * Histologically determined adenocarcinoma is required. * All other histologies are excluded. * Tissue for diagnosis must be obtained by transrectal ultrasound biopsy. * Gleason scoring classification of the biopsy specimen is required and must be greater than or equal to 7. * 2002 AJCC clinical cancer stage as determined by either urologist or radiation oncologist must be T1c - T2b, N0, M0. * N0 stage may be assigned following either negative imaging or negative pathologic assessment. * Prostate volume as assessed by TRUS must be less than 60 cc. 3.1.5. * PSA must be less than 20 ng/ml. , * Age ≥ 18, * IPSS voiding symptoms score must be less than 18, * Study consent form must be signed by the patient. Exclusion Criteria: * Gleason score of 8 - 10, * Clinical stage T3 - T4, * Age ≤ 18, * Any evidence of nodal (N1) or distant (M1) disease, * Prostate volume as assessed by TRUS \> 60 cc, * PSA \> 20 ng/ml, * IPSS voiding symptoms score \> 18, * Prior TURP, * Prior pelvic radiotherapy or chemotherapy, * Prior prostatectomy, * Prior cancer other than basal cell or squamous cell skin carcinoma unless free of disease for \> 5 years, * Current medical or psychiatric illness that may interfere with treatment completion and followup, * Hip prosthesis, * Unable or unwilling to give informed consent